Pacira BioSciences (PCRX) reported second-quarter 2026 total revenue of $192.4 million, up 6% from $181.1 million a year earlier. GAAP net income was $4.7 million, or $0.12 per share basic and diluted, compared with a GAAP net loss of $4.8 million, or $0.11 per share, in the prior-year quarter.
The company also completed the divestiture of its iovera° business to Zimmer Biomet after quarter-end and updated its full-year 2026 revenue guidance to $735 million to $760 million.
- Total revenues were $192.4 million in Q2 2026, including total net product sales of $190.5 million.
- EXPAREL net product sales rose 3% year over year to $147.8 million.
- ZILRETTA net product sales rose 4% to $32.6 million.
- iovera° net product sales increased 22% to $6.8 million before the divestiture closed on July 31, 2026.
- Pacira ended the quarter with $251.0 million in cash, cash equivalents and available-for-sale investments.
- The company expects full-year 2026 EXPAREL net product sales of $600 million to $620 million.
$PCRX Insider Trading Activity
$PCRX insiders have traded $PCRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 4 sales selling 25,000 shares for an estimated $628,193.
- KRISTEN WILLIAMS (Chief Administrative Officer) sold 10,259 shares for an estimated $228,467
- LAUREN RIKER (Senior Vice President, Finance) sold 6,115 shares for an estimated $143,702
- JONATHAN SLONIN (Chief Medical Officer) sold 3,261 shares for an estimated $74,416
- MARK FROIMSON sold 500 shares for an estimated $10,905
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PCRX Hedge Fund Activity
We have seen 105 institutional investors add shares of $PCRX stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 839,561 shares (-88.8%) from their portfolio in Q1 2026, for an estimated $18,974,078
- AMERICAN CENTURY COMPANIES INC removed 498,484 shares (-37.3%) from their portfolio in Q1 2026, for an estimated $11,265,738
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 409,997 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,265,932
- J. GOLDMAN & CO LP removed 339,481 shares (-77.6%) from their portfolio in Q1 2026, for an estimated $7,672,270
- BLACKROCK, INC. removed 328,937 shares (-4.7%) from their portfolio in Q1 2026, for an estimated $7,433,976
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 303,832 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,866,603
- GOLDMAN SACHS GROUP INC added 269,529 shares (+20.7%) to their portfolio in Q1 2026, for an estimated $6,091,355
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
